Protagenic’s PT00114 Breakthrough: New Hope for Stress Disorders by Mark Eisenberg 13.02.2024 Protagenic Therapeutics achieves milestone in Phase I trial for PT00114, a compound for treating stress-related neuro-psychiatric disorders. No adverse reactions ...